Amyris: Acquisition Of Oobli To Expand Sweet Protein Technology And Precision Fermentation Capabilities

Amyris, a vertically integrated biomanufacturing company, has announced an agreement to acquire Oobli, a developer of fermentation-produced sweet proteins used to reduce sugar in food and beverage products. The acquisition will combine Amyris’ strain engineering and industrial fermentation capabilities with Oobli’s proprietary sweet protein technology, expanding the company’s presence in alternative sweeteners and protein-based ingredients.

The transaction follows Amyris’ expansion of manufacturing capacity at its advanced fermentation facility in Barra Bonita, Brazil, earlier in 2026.

Amyris plans to use its commercial and manufacturing resources to accelerate adoption of Oobli’s sweet protein ingredients across food, beverages, nutrition, and other markets.

The acquisition is expected to close in the coming weeks.

The companies said existing customer commitments and brand partnerships will continue without interruption as they prepare for the combination.

Oobli Develops Fermentation-Based Sweet Proteins

Oobli has spent approximately a decade developing technology to produce sweet proteins through fermentation.

These proteins occur naturally in certain rare fruits and berries found in regions near the equator.

Because the original botanical sources are not well suited to large-scale commercial production, Oobli has developed fermentation processes intended to produce the proteins more efficiently.

Its portfolio includes sweet proteins associated with Oubli Fruit, Serendipity Berry, and Katemfe Fruit.

The corresponding proteins are known scientifically as brazzein, monellin, and thaumatin.

According to Oobli, these proteins can be hundreds to thousands of times sweeter than conventional sugar.

They create a sweet taste by interacting with sweet taste receptors.

The company believes these characteristics can make sweet proteins useful in reducing added sugar while preserving flavor.

Unlike conventional sugar molecules, sweet proteins are metabolized as proteins.

Oobli says its ingredients can deliver sweetness without the blood sugar spikes associated with conventional sugar consumption.

These claims reflect the company’s description of its technology, and the effects of a finished food product will depend on its complete formulation.

Regulatory Status And Food Industry Applications

Oobli’s sweet protein portfolio has Generally Recognized as Safe (GRAS) status for specified ingredient uses under the applicable FDA framework.

The company also reports FEMA GRAS affirmation for use as a natural flavor.

These designations support the use of the ingredients in qualifying food and beverage applications, subject to relevant conditions.

Oobli is targeting several product categories where manufacturers are seeking alternatives to conventional sugar.

Potential applications include sports nutrition, dairy products, beverages, chocolate, bakery products, and confectionery.

Food and beverage companies are increasingly evaluating ingredients that can help them reduce sugar without significantly changing product taste.

However, replacing sugar can be technically challenging because sugar contributes not only sweetness but also texture, structure, and other functional properties.

Oobli’s technology provides manufacturers with an additional ingredient option for product formulation.

Amyris believes its industrial fermentation capabilities can help bring these proteins to a broader range of customers.

Amyris Adds Protein And Peptide Manufacturing Expertise

Amyris develops and manufactures specialty molecules using advanced fermentation technology.

Its operations span industries including flavors and fragrances, personal care, beauty, food, and advanced materials.

The company combines strain engineering with manufacturing processes designed to produce specialty ingredients at commercial scale.

Strain engineering involves modifying or optimizing microorganisms to produce desired compounds through fermentation.

Oobli’s protein production technology will add specialized capabilities to Amyris’ existing scientific and manufacturing platform.

The acquisition also supports the company’s expansion into protein- and peptide-based products.

Amyris believes the combined technology can create opportunities beyond sweeteners.

Potential markets include food and beverages, personal care, agriculture, flavors and fragrances, and other specialty ingredient applications.

The company intends to use Oobli’s existing sweet protein portfolio as the initial focus of the combined platform.

Expanded Brazilian Manufacturing Capacity Supports Growth

The acquisition follows Amyris’ recent manufacturing expansion at its Barra Bonita fermentation facility in Brazil.

The site provides industrial production capacity for fermentation-derived specialty ingredients.

Amyris expects its expanded infrastructure to support commercialization of technologies developed by Oobli.

Scaling fermentation-based ingredients can require substantial manufacturing expertise involving production processes, purification, quality control, and cost optimization.

Amyris believes its existing infrastructure and operational experience can help Oobli expand production.

The transaction is intended to combine Oobli’s expertise in sweet protein development with Amyris’ ability to manufacture specialty molecules commercially.

The companies also see opportunities to expand customer relationships through a broader ingredient portfolio.

Growing Demand For Sugar Reduction Ingredients

The acquisition reflects continued interest in food ingredients that support sugar reduction.

Manufacturers are developing products intended to address consumer preferences involving sweetness, ingredient composition, and metabolic health.

Alternative sweeteners include conventional high-intensity sweeteners, sugar alcohols, and other technologies.

Sweet proteins represent another approach because they use protein molecules to activate sweet taste receptors.

Oobli believes its ingredients can help manufacturers achieve desired sweetness levels while reducing reliance on conventional sugar.

Amyris expects the acquisition to strengthen its position in this category through increased production capacity and commercial resources.

The companies plan to maintain existing customer and brand relationships as the transaction progresses.

Supporting Long-Term Biomanufacturing Expansion

Amyris CEO Kathy Fortmann described Oobli’s technology as complementary to the company’s existing capabilities.

She highlighted opportunities to combine protein expertise with strain engineering, fermentation infrastructure, and commercial distribution.

Oobli CEO Ali Wing said joining Amyris will provide resources to support broader deployment of sweet proteins.

The acquisition will expand Amyris’ portfolio of fermentation-derived ingredients while providing Oobli with access to an established biomanufacturing platform.

The deal is expected to close within weeks of its November 12, 2026 announcement.

Once completed, Amyris intends to advance commercialization of Oobli’s sweet protein portfolio while exploring additional applications for protein-based manufacturing technologies.

KEY QUOTES:

“In Oobli, we see a commercial and technology platform that is a great complement to our own. Oobli is poised to transform how sweetness makes it to market, and we are thrilled to bring our commercial scale and resources to further accelerate the sweet revolution. Further, by bringing Oobli’s protein expertise together with our strain engineering, manufacturing scale, and commercial capabilities, we see the potential to broaden our capabilities in food and beverage, personal care, flavor and fragrances, agriculture, and beyond, expanding the ways we can help customers innovate.”

Kathy Fortmann, CEO Of Amyris

“At Oobli, we have always believed there was a better way to deliver the sweet taste consumers love, without the trade-offs to health and our environment. It is with immense pride that we look back on the breakthroughs we have achieved. Joining forces with Amyris gives us the scale and resources to realize our ambition of making sweet proteins the global standard in sweetness solutions. Sweet proteins are an idea whose time is now.”

Ali Wing, CEO Of Oobli

“At Amyris, we’ve seen that biomanufactured solutions win when they align with consumer demand and market needs. Oobli’s sweet protein platform does exactly that – giving brands a new way to deliver on sweet taste, sugar reduction, and clean label all at the same time. We could not be more excited to welcome the Oobli team into the Amyris family and collectively realize the synergies between our two innovative platforms.”

Kathy Fortmann, CEO Of Amyris